You are here

Article Text

Article menu

Download PDFPDF

Other topics
Tumour necrosis factor antagonists and tocilizumab have a higher impact on rheumatoid arthritis osteoclastogenic stimuli than methotrexate
Free
  1. I Perpétuo1,
  2. D Fernandes1,
  3. R Cascão1,
  4. R Moura1,
  5. J Caetano-Lopes1,
  6. A Rodrigues1,2,
  7. J Polido-Pereira1,2,
  8. M Viana Queiroz2,
  9. J E Fonseca1,2,
  10. H Canhão1,2
  1. 1Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular/Faculdade de Medicina de Lisboa
  2. 2Rheumatology and Bone Metabolic Diseases Department, Hospital de Santa Maria, Lisboa, Portugal

https://doi.org/10.1136/ard.2010.129643p

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Background

    Rheumatoid arthritis (RA) is a systemic disease characterised by hyperactivation of the immune system leading to chronic inflammation and joint damage. The inflammatory environment potentiates bone resorption, modulating the balance between RANKL and osteoprotegerin (OPG). Prednisone (PDN), methotrexate (MTX), anti-tumour necrosis factor (TNF) and anti-interleukin 6 (IL6) receptor therapies reduce disease activity, but their differential biological impact …

    View Full Text